Skip to main content
Clinical Trials/NL-OMON50835
NL-OMON50835
Completed
Not Applicable

Phase I, Randomized, double-blind, vehicle-controlled study to evaluate the safety, tolerability, PK and efficacy of M528101 in Healthy Volunteers and AD subjects - Phase I study of M528101

Maruho Co,Ltd0 sites36 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Atopic Dermatitis
Sponsor
Maruho Co,Ltd
Enrollment
36
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Subjects who meet all of the following criteria are eligible to participate in
  • this study:
  • 1\. Healthy male subjects, 18 to 45 years of age, inclusive. Healthy status is
  • defined by absence of evidence of any active or chronic disease following a
  • detailed medical and surgical history, a complete physical examination
  • including vital signs, 12\-lead ECG, hematology, blood chemistry, blood serology
  • and urinalysis;
  • 3\. Body mass index (BMI) between 18 and 30 kg/m2, inclusive, and with a minimum
  • weight of 50 kg;
  • 3\. Subjects must use effective contraception for the duration of the study;

Exclusion Criteria

  • Exclusion Criteria part A
  • 1\. Any disease associated with immune system impairment, including auto\-immune
  • diseases, allergies, HIV and transplantation patients;
  • 2\. History of pathological scar formation (keloid, hypertrophic scar);
  • 3\. Excessive sun exposure or a tanning booth within 21 days prior to Day 1;
  • 4\. Participation in an investigational drug or device study within 3 months
  • prior to screening or more than 4 times a year;
  • 5\. Loss or donation of blood over 500 mL within three months prior to
  • screening. Or the donation of plasma within 14 days prior to screening;
  • 6\. Current smoker and/or regular user, of other nicotine\-containing products

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
A Clinical Trial which compare the safety and efficacy of a wound gel, the study treatment, or a sunflower oil-based vehicle gel in patients with Inherited Epidermolysis Bullosa (EB)
EUCTR2016-002066-32-HRAmryt Research Limited192
Active, not recruiting
Phase 1
A Clinical Trial which compare the safety and efficacy of a wound gel, the study treatment, or a sunflower oil-based vehicle gel in patients with Inherited Epidermolysis Bullosa (EB)Inherited Epidermolysis BullosaMedDRA version: 20.0Level: PTClassification code 10014989Term: Epidermolysis bullosaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
EUCTR2016-002066-32-ATAmryt Research Limited250
Active, not recruiting
Phase 1
A Clinical Trial which compare the safety and efficacy of a wound gel, the study treatment, or a sunflower oil-based vehicle (placebo) gel in patients with Inherited Epidermolysis Bullosa (EB)Inherited Epidermolysis BullosaMedDRA version: 20.0 Level: PT Classification code 10014989 Term: Epidermolysis bullosa System Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
EUCTR2016-002066-32-GRAmryt Research Limited250
Active, not recruiting
Phase 1
A Clinical Trial which compare the safety and efficacy of a wound gel, the study treatment, or a sunflower oil-based vehicle gel in patients with Inherited Epidermolysis Bullosa (EB)Inherited Epidermolysis BullosaMedDRA version: 20.0Level: PTClassification code 10014989Term: Epidermolysis bullosaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
EUCTR2016-002066-32-IEAmryt Research Limited250
Active, not recruiting
Phase 1
A Clinical Trial which compare the safety and efficacy of a wound gel, the study treatment, or a sunflower oil-based vehicle gel in patients with Inherited Epidermolysis Bullosa (EB)
EUCTR2016-002066-32-BEAmryt Research Limited192